[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seasonal-allergic-rhinitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seasonal-allergic-rhinitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,85,110,134,156,177,204,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100404318","the-role-of-the-nasal-allergen-provocation-test-in-starting-and-monitoring-allergen-immunotherapy-100404318",false,"NCT04544774","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy: An Academic Multicentre Clinical Study","Inclusion Criteria:\n\n* Age \\>18 and ≤60 years\n* Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and\u002Fof immunocap for the specific IgEs.\n\nOR suspected local allergic rhinitis\n\n* Patients who start with AIT treatment\n* The patient must be motivated and willing to come to all visits\n* The patient must be able to understand and sign the informed consent\n\nExclusion Criteria:\n\n* Uncontrolled asthma\n* Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases)\n* Use of β-blockers, immunosuppressants or ACE inhibitors\n* Hypersensitivity to aluminum hydroxide and\u002For hypersensitivity to any of the excipients in AIT\n* Anaphylaxis after allergen challenge in the past\n* Acute rhinosinusitis in the last 12 weeks\n* Recent surgery on the nose and\u002For paranasal sinuses in the last 12 weeks\n* Pregnancy","ALL","18 Years","60 Years",{"count":20,"type":21},200,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy.\n\nThe NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years.\n\nThis study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine \u002F Allergology",[26,27,28],"Perennial Allergic Rhinitis","Seasonal Allergic Rhinitis","Local Allergic Rhinitis","RECRUITING","2026-04-30",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2020-07-16",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Universitaire Ziekenhuizen KU Leuven","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100597211","creating-a-risk-assessment-tool-for-thunderstorm-asthma-the-carista-study-100597211","NCT07055542","Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study","Creating A RIsk Assessment Biomarker Tool to Prevent Seasonal and Thunderstorm Asthma: The CARISTA Study","CARISTA","Inclusion Criteria:\n\nConsenting adults aged 18 to 70 years with seasonal allergic rhinitis\n\nwilling to undertake:\n\n* Lung function testing\n* Blood sample collection for risk factor identification, -Prospectively logging their symptoms and medications through the springtime season using the CARISTA symptom monitoring platform . -\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent\n* Individuals who do not suffer from symptoms of seasonal allergic rhinitis\n* Individuals who do not consent to lung function testing and blood sample collection - Individuals with unstable asthma (FEV1 by spirometry less than 70% predicted), a recent exacerbation or change of asthma preventive medication use (within one month) would be excluded, although re-screening would be permitted after one month, time permitting.\n* Individuals with severe asthma requiring the use of continuous oral corticosteroids or biological medication for severe asthma.\n* The presence of any medical illness, such as cardiac disease, pre-existing illness or immunomodulatory therapy that, in the opinion of the Investigators, would compromise participant safety or the derivation of biomarkers during the study.",true,"70 Years",{"count":53,"type":21},530,"INTERVENTIONAL",[56],"NA","Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.",[59,60,27,61,62,63],"Allergic Asthma","Thunderstorm Asthma","Grass Pollen Allergy","Asthma Exacerbation Due to Thunderstorm","Asthma Acute",[65,66,67,68,69,70,71,72,73,74],"asthma","allergy","grass pollen allergy","ryegrass pollen","prospective symptom monitoring","seasonal allergic rhinitis","hay fever","seasonal allergic rhinoconjunctivitis","serum specific IgE","spirometry","2026-04-29",{"date":77,"type":33},"2026-05-06",{"date":79,"type":33},"2025-08-27",{"date":81,"type":21},"2030-12-31",{"name":83,"class":40},"University of Melbourne",6,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":54,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100623609","phase-2-clinical-study-on-tqh2722-injection-combined-with-background-therapy-for-seasonal-allergic-rhinitis-100623609","NCT07398859","Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis","A Multi-center, Open-label, Phase II, Single-arm Clinical Study Evaluating the Safety and Efficacy of TQH2722 Injection Combined With Background Treatment in Subjects With Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n* Aged 18-75, with no gender restrictions.\n* Diagnosed with seasonal allergic rhinitis.\n* Positive allergen test result.\n* The subjects have sufficient exposure to pollen during the pollen season.\n* The subject's medical history indicates that the subject had poor control of Seasonal Allergic Rhinitis (SAR) symptoms during the previous pollen season or the subject was dissatisfied with the subjective symptom control.\n* Screen for subjects who have a morning iTNSS score of ≥4 on the day of screening; at baseline visit, have a morning iTNSS score of ≥4, and have an average rTNSS score of ≥4 over the past 6 days.\n* Good compliance during screening\u002Finduction period.\n* Subjects with comorbid asthma should have stable medication use before the screening period and have their asthma condition assessed as stable by the investigator or specialist.\n* The subjects voluntarily joined this study, signed the informed consent form, and exhibited good compliance.\n* The subjects and their partners agree to take effective contraceptive measures throughout the entire study period (from the signing of the Informed Consent Form (ICF) to 3 months after the last administration of the trial drug).\n\nExclusion Criteria:\n\n* Any abnormal laboratory test value during the screening period or randomization.\n* Any disease that researchers consider to be unstable and may affect the patient's safety throughout the entire study period, or affect the study results or their interpretation, or hinder the patient's ability to complete the entire study process.\n* Patients with active autoimmune diseases.\n* Known or suspected immunosuppressants.\n* Subjects with active malignant tumors or a history of malignant tumors.\n* Screen for individuals with a history of active tuberculosis within the previous 12 months.\n* During the screening period, there is active hepatitis, or the presence of human immunodeficiency virus antibody (Anti-HIV) positivity, or syphilis treponema antibody (Anti-TP) positivity.\n* Screen for cases diagnosed with helminthic parasitic infections within the previous 6 months, who have not undergone standard treatment or have experienced ineffective standard treatment.\n* Subjects who have received specific medications or undergone any nasal or sinus surgery within the specified timeframe.\n* Intravenous immunoglobulin (IVIG) therapy and\u002For plasma exchange within 30 days before screening.\n* Screen subjects who have used monoamine oxidase inhibitors within the previous 14 days.\n* Initiate allergen immunotherapy within 3 months prior to screening.\n* Screen for individuals who have received attenuated live vaccines within the previous 4 weeks or plan to receive attenuated live vaccines during the study period.\n* Screen for systemic Chinese herbal preparations used for the treatment of AR with short- or medium-acting systemic glucocorticoids within 4 weeks, or screen for long-acting Systemic Corticosteroids (SCS) received within the previous 6 weeks.\n* Suffering from chronic active or acute infection within 2 weeks before screening or during the screening and import period.\n* Patients with concomitant asthma should be excluded if they meet any of the following conditions: a. forced expiratory volume in one second (FEV1) ≤ 50% of the predicted normal value; b. acute exacerbation of asthma within 90 days prior to screening; c. currently using fluticasone propionate at a daily dose of \\>1000 μg\u002Fday or equivalent doses of other inhaled corticosteroids; d. assessed by the investigator or specialist as having unstable asthma.\n* The subject has a concomitant disease that renders them unable to complete the screening period assessment or evaluate the primary efficacy endpoint.\n* Suffering from malignant and benign tumors in the nasal cavity.\n* Subjects with perennial allergic rhinitis (PAR) who are allergic to pet hair.\n* Unable to use nasal corticosteroid sprays or antihistamines.\n* Have a history of systemic allergy to any biological agents.\n* Women who are pregnant or breastfeeding.\n* Individuals who abuse alcohol, use drugs, and have known drug dependency.\n* History of major organ transplantation or hematopoietic stem cell\u002Fbone marrow transplantation.\n* According to the researcher's judgment, there are any medical or psychiatric symptoms that may put the subjects at risk, interfere with their participation in the study, or interfere with the interpretation of the study results.\n* The forced expiratory volume in one second (FEV1) of the subject is less than or equal to 50% of the predicted normal value.\n* Other reasons why the researcher believes it is inappropriate to participate in this trial.","75 Years",{"count":94,"type":21},300,[96],"PHASE2","This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.",[27],"2026-03-26",{"date":101,"type":33},"2026-03-27",{"date":103,"type":33},"2026-03-19",{"date":105,"type":21},"2027-03",{"name":107,"class":108},"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","INDUSTRY",30,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":54,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100626484","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-ak139-in-participants-with-seasonal-allergic-rhinitis-100626484","NCT07436234","A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis","A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe SAR","Inclusion Criteria:\n\n1. Male or female aged 18-65.\n2. Able to understand the study and voluntarily sign the ICF;\n3. Diagnosed SAR according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition), with or without allergic conjunctivitis, and have SAR history at least two years;\n4. Have immunoglobulin E (Ig E)-mediated hypersensitivity to at least one pollen allergen in the current environment;\n5. The SAR symptoms of participants remained inadequately control ledafter nasal spray corticosteroids and\u002For other SAR medications treatment throughout the previous same pollen season;\n6. Adequate pollen exposure during the pollen season.\n7. The SAR symptoms scores of the participants meet the requirements of the protocol at screening and baseline.\n8. During the screening\u002Frun-in period, participants must complete at least 80% of the assessments in the diary card;\n9. The participants agree to use highly effective contraception methods from the moment of signing of the ICF to 3 months after the last dose of the investigational product.\n\nExclusion Criteria:\n\n1. Type of rhinitis other than allergic rhinitis within 2 weeks before screening;\n2. Allergic to any component of the investigational drug or intolerant to basis treatment..\n3. Concomitant or associated nasal diseases\u002Fconditions that, as determined by investigators, may affect the severity of the disease and the evaluation of therapeutic effects.\n4. Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to.\n5. Other reasons the investigators believes that the participants is not suitable to enrolled in this study.","65 Years",{"count":119,"type":21},111,[96],"This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR",[27],"NOT_YET_RECRUITING","2026-02-25",{"date":126,"type":33},"2026-02-27",{"date":128,"type":21},"2026-03-02",{"date":130,"type":21},"2027-05-13",{"name":132,"class":108},"Akeso",1,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":142,"targetDuration":4,"studyType":54,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":133},"100539158","phase-2-study-of-cm310-in-patients-with-uncontrolled-seasonal-allergic-rhinitis-100539158","NCT06300203","Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis","The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment： A Randomized, Double-Blind, Placebo-controlled IIT Study","MEGREZ","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Have any condition that are not suitable for participating in this study.",{"count":143,"type":21},120,[96],"Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.",[27],"2025-09-20",{"date":149,"type":33},"2025-09-25",{"date":151,"type":33},"2024-03-18",{"date":153,"type":21},"2026-06-30",{"name":155,"class":40},"Beijing Tongren Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":163,"targetDuration":4,"studyType":54,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":133},"100599966","phase-2-a-clinical-study-on-the-efficacy-safety-pharmacokinetics-and-pharmacodynamics-of-shr-1819-injection-in-patients-with-seasonal-allergic-rhinitis-100599966","NCT07091357","A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n1. At the time of signing the informed consent form, the age is 18 to 75 years old.\n2. Meet the diagnostic criteria for seasonal allergic rhinitis (SAR) as defined in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition), with or without allergic conjunctivitis, and have a disease duration of at least 2 years.\n3. At the screening visit, the investigator assesses that the subject had poor efficacy with intranasal glucocorticoids and\u002For other medications for allergic rhinitis (antihistamines, leukotriene receptor antagonists, etc.) during the same pollen season in the past.\n4. The subject has an immunoglobulin E (IgE)-mediated hypersensitivity to at least one pollen allergen in the current season or the same period, which can be confirmed based on the skin prick test (SPT) and\u002For serum specific IgE results during the screening period (test results within 1 year before randomization are acceptable).\n5. Willing and able to complete the patient diary as required by the protocol during the study period.\n6. Female subjects of childbearing potential and male subjects whose partners are females of childbearing potential agree to use the contraceptive measures specified in the protocol from the signing of the ICF until 3 months after the last administration.\n\nExclusion Criteria:\n\n1. During screening or within 2 weeks prior to the screening visit, the subject has other active rhinitis excluding SAR, including but not limited to infectious rhinitis, drug-induced rhinitis, vasomotor rhinitis, non-allergic rhinitis with eosinophilia syndrome, dry rhinitis, atrophic rhinitis, etc.\n2. During screening or within 2 weeks prior to the screening visit, there may be other nasal comorbidities or concurrent diseases\u002Fstates that could affect the judgment of efficacy (including but not limited to nasal polyps, cerebrospinal fluid rhinorrhea, severe nasal septal deviation, status after nasal or sinus surgery within 1 year, etc.), acute\u002Fchronic sinusitis (except those deemed non-influential by the investigator), or upper respiratory tract infections.\n3. During screening, there is glaucoma, cataract, ocular simple herpes, other ocular infections such as infectious conjunctivitis, acute conjunctivitis, acute keratitis (except for symptoms related to allergic rhinitis).\n4. During the screening visit, subjects with perennial allergic rhinitis (PAR) allergic to pet hair are included; if the subject currently has no contact with pet hair, they can be enrolled.\n5. Subjects with severe asthma who are receiving treatment with inhaled glucocorticoids (ICS) at a daily high dose or equivalent of more than twice the standard dose.\n6. Subjects who initiated ICS treatment for asthma within 4 weeks prior to the screening visit. If the subject has been treated with a stable dose of ICS for at least 4 weeks before the screening visit, and the ICS dosage does not exceed twice the daily high dose, and the investigator assesses that the asthma remains well-controlled during the study while maintaining this dosage, such subjects may be screened.\n7. Within 3 months prior to the screening visit, the subject had an acute exacerbation of asthma requiring hospitalization for more than 24 hours.\n8. Within 6 months prior to the screening visit, the subject has a history of vernal keratoconjunctivitis (VKC) and\u002For atopic keratoconjunctivitis (AKC).\n9. Within 1 week prior to randomization, the subject has received treatment with the following medications: leukotriene receptor antagonists. If the subject has been stably using mast cell membrane stabilizers, decongestants, nasal anticholinergic drugs, or other nasal preparations that may affect SAR assessment for ≥1 week at the time of screening, they may be included.\n10. Within 2 weeks prior to the screening visit, the subject has used monoamine oxidase inhibitors.\n11. Within 4 weeks prior to the screening visit, the subject has received the following treatments: systemic glucocorticoids, systemic immunosuppressants (including but not limited to hydroxychloroquine, cyclosporine, azathioprine, methotrexate, cyclophosphamide, tacrolimus, etc.), systemic traditional Chinese medicines (including proprietary Chinese medicines) for treating allergic rhinitis, and tricyclic antidepressants.\n12. Within 4 weeks prior to the screening visit, the subject initiated immunotherapy or plans to receive immunotherapy during the study. If the subject has maintained a stable dose of immunotherapy for 4 weeks before screening and can continue this dose throughout the study, they may be enrolled.\n13. Within 8 weeks prior to the screening visit or within 5 half-lives (if the half-life is known) of receiving investigational drugs or medical devices, whichever is longer. If the subject participated in a clinical study but only signed the informed consent form, and it can be proven that screening failed and no medication was administered, they may be enrolled.\n14. Within 3 months prior to the screening visit, the subject has received or been exposed to other live vaccines or live attenuated vaccines, or participated in a vaccine clinical trial.\n15. Within 6 months prior to the screening visit, the subject has used other biological agents.\n16. Within 1 week prior to the screening visit, the subject requires systemic antimicrobial treatment (for viral, bacterial, fungal, or parasitic infections).\n17. At the time of screening and within 2 weeks prior to screening, positive results for human immunodeficiency virus antibody (HIV), syphilis antibody, and hepatitis C virus (HCV) antibody; hepatitis B virus (HBV) infection meets the following (test results within 2 weeks prior to screening are acceptable).\n18. Within 3 months prior to the screening visit, the subject has undergone major surgery, or plans to undergo major surgery during the study period.\n19. Within 6 months prior to the screening visit, the subject was diagnosed with active tuberculosis.\n20. Within 6 months prior to the screening visit, the subject was diagnosed with or the investigator determined the presence of suspected immunosuppressive diseases.\n21. Within 1 year prior to the screening visit, the subject has a history of recurrent herpes zoster or Kaposi varicelliform eruption (≥2 times), disseminated herpes zoster, or disseminated herpes simplex.\n22. Has or has a history of malignant tumor (except for cutaneous squamous cell carcinoma, basal cell carcinoma, or cervical in situ carcinoma that has been completely resected and shows no evidence of recurrence).\n23. Accompanied by other severe or chronic diseases that are poorly controlled.\n24. Pregnant or lactating women.\n25. Within 6 months prior to screening, the subject has a history of alcohol abuse.\n26. The investigator determines that there are conditions affecting the safety and efficacy evaluation of the study drug, as well as any other circumstances that may lead to the patient's non-compliance with the trial procedures and log filling.",{"count":164,"type":21},100,[96],"This is a trial to evaluate the safety and efficacy of SHR-1819 injection in the treatment of patients with seasonal allergic rhinitis.",[27],"2025-09-01",{"date":170,"type":33},"2025-09-03",{"date":172,"type":33},"2025-08-06",{"date":174,"type":21},"2025-12",{"name":176,"class":108},"Guangdong Hengrui Pharmaceutical Co., Ltd",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":185,"targetDuration":4,"studyType":54,"phases":187,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100604177","phase-3-a-phase-iii-study-to-assess-the-efficacy-and-safety-of-pg-011-nasal-spray-in-adults-with-moderate-to-severe-seasonal-allergic-rhinitis-100604177","NCT07146126","A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb\u002FIII Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis","Pumecitinib","Inclusion Criteria:\n\n1. Male or female aged 18 to 65 (including threshold).\n2. Reflective total nasal symptom score ( rTNSS) score≥ 6 and retrospective nasal obstruction ≥ 2 on the day of screening visit, D-4 and D1. Meanwhile, the baseline average rTNSS score(Calculated as the average of rTNSS score of D-3, D-2, D-1 morning, D-1 evening, and D1 morning) ≥ 6\n3. History of SAR for at least 2 years. and positive results for any local allergen in the current season tested by either the skin prick test (SPT) (where the wheal diameter is at least 5 mm larger than that of the negative control) or the serum - specific IgE (sIgE) test (the sIgE test results obtained within ≤ 1 year before random enrollment are acceptable).\n4. Willingness to avoid pregnancy or fathering children from the signing of the informed consent form until three month after after the end of the study.\n5. Willing to sign the informed consent form and abide by the research protocol.\n\nExclusion Criteria:\n\n1. Participants are diagnosed of active or latent tuberculosis infection.\n2. Participants are diagnosed of moderate to severe asthma.\n3. Participants who had active pulmonary diseases or infections, upper respiratory tract infections or sinus infections within 2 weeks before screening, and\u002For those who had respiratory infections during the lead-in period.\n4. Participants received nasal or sinus surgery within 3 months before screening or had nasal trauma that had not fully healed.\n5. Any nasal mucosal erosion, nasal septal ulcer or nasal septal perforation, as judged by the investigator, may affect the deposition of drugs in the intranasal, such as acute or chronic sinusitis, drug-induced rhinitis, nasal polyps, etc.\n6. Participants has ocular herpes simplex or other ocular infections (except seasonal allergic conjunctivitis).\n7. Participants with facial or systemic fungal, bacterial, viral or parasitic infections, or oral infections that had not been cured and still required continuous treatment within 4 weeks before screening.\n8. Participants have severe diseases such as central nervous system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system or blood system, which may affect the judgment of efficacy and safety .\n9. Participants who were infected with human immunodeficiency virus (HIV) at the time of screening, those in the active stage of hepatitis C virus (HCV) infection, those in the active stage of hepatitis B virus (HBV) infection (HBV - DNA \\> 2000 IU\u002FmL or 10⁴ copies\u002FmL), or those with positive Treponema pallidum antibody indicating an active stage of infection.\n10. Any drug treatments before lead-in period, such as use of nasal or systemic decongestants and anticholinergic drugs within 3 days, use of antihistamines such as cetirizine, fexofenadine, and loratadine within 5 days, systemic use of glucocorticoids within 4 weeks, mast cell stabilizers, tricyclic antidepressants, and leukotriene receptor antagonists within 2 weeks, and use of anti - allergic Chinese herbal medicines within 2 weeks, use of anti-interleukin-4 receptor α subunit (IL-4Rα) monoclonal antibody such as thymic matrix lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonal antibody, other monoclonal antibody, or other biologics within 10 weeks or 5 half-lives (whichever is longer).\n11. During the trial, participants who cannot stop using JAK inhibitors, tricyclic antidepressants, glucocorticoids, decongestants, antihistamines (except loratadine, which is a rescue drug required during the treatment), leukotriene receptor antagonists, mast cell stabilizers (including sodium cromoglycate, nedocromil sodium, tetrazolium chromone, nedocromil sodium, pemirolast potassium, and tranilast, etc.), anticholinergic drugs, anti - allergic Chinese herbal medicines, and those who cannot stop using nasal irrigation.\n12. Participants who have undergone desensitization therapy or received immunotherapy within 6 months prior to screening.\n13. Participants who are known or judged by the investigator to potentially have an allergic reaction to the active ingredients or excipients of the investigational drug.\n14. Participants who have a history of intolerance to intranasal administration.\n15. Participants who plan to travel outside the local area for 2 consecutive days or more during the trial.\n16. Participants who have participated in other clinical studies of investigational drugs or medical devices within 3 months prior to screening and have used investigational products.\n17. Participants who have a history of drug abuse or alcoholism within 1 year prior to screening\n18. Female participants who are breastfeeding or pregnant at the time of screening\n19. Reproductive - age participants (male or female) who plan to become pregnant, breastfeed, or donate sperm\u002Feggs during the study or within 1 month after the study ends\n20. Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for participation in the study",{"count":186,"type":21},600,[188],"PHASE3","The study is a multicenter, randomized, double-blind, placebo-controlled seamless and adaptive-designed phase IIb\u002FIII study encompassing a phase IIb and a phase III component, phase IIb is a dose-ranging part and has been done, and phase III is a pivotal study part which is registered this time.\n\nThe goal of this phase III study is to evaluate the efficacy, safety, and pharmacokinetics of PG-011 nasal spray for treating adults with moderate to severe seasonal allergic rhinitis (SAR). Investigators will compare PG-011 nasal spray to a placebo (a look-alike substance that contains no drug) to see if PG-011 nasal spray works to treat moderate to severe seasonal allergic rhinitis",[27,191],"SAR",[191,193,27,183],"PG-011","2025-08-21",{"date":196,"type":33},"2025-08-28",{"date":198,"type":21},"2025-09-15",{"date":200,"type":21},"2026-07-30",{"name":202,"class":108},"Prime Gene Therapeutics Co., Ltd.",38,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":211,"targetDuration":4,"studyType":54,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":133},"100425112","acupuncture-at-the-sphenopalatine-ganglion-in-the-treatment-of-moderate-to-severe-seasonal-allergic-rhinitis-100425112","NCT04815668","Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis","Effect of Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤ 75 years;\n2. History of moderate to severe SAR symptoms (Visual analog scale(VAS) \\>50 mm, range, 0 cm\\[not at all bothersome\\] to 100 mm\\[extremely bothersome\\]) for more than 4 days\u002Fweeks, and more than 4 consecutive weeks with at least two years' duration;\n3. Positive skin prick test to grass and birch pollen or\u002Fand serum-specific IgE test;\n4. Ability to complete the medical information form and sign a written informed consent.\n\nExclusion Criteria:\n\n1. History or current evidence of perennial allergic rhinitis, acute sinusitis, allergic asthma, pneumonia; autoimmune disorders, or severe chronic inflammatory diseases;\n2. History of nasal rhinopolypus or abnormalities;\n3. Intake of antihistamines, anticholinergics, corticosteroids, decongestants, or antibiotics during the 1 month prior to beginning the study;\n4. History of systemically administered corticosteroids within 6 months or specific immunotherapy, allergy desensitization therapy within 1 year before enrollment;\n5. Serious uncontrolled blood coagulation disorder, cardiovascular disorder, severe hepatic\u002Frenal insufficiency or mental disorder;\n6. Pregnancy or planning for pregnancy;\n7. Known allergy, or contraindication to rescue medication or related drugs;\n8. Known phobia to acupuncture or having received acupuncture treatment, or sphenopalatine ganglion stimulation or other complementary and alternative medicine within 1 months prior to enrollment.",{"count":143,"type":21},[56],"Allergic rhinitis (AR) is an immunoglobulin E-mediated inflammatory disease1 caused by hypersensitivity of the immune system to an allergen, affecting 100 million people in Europe 2and 400 million of the global population.The etiology of AR is multifactorial, resulting primarily from genetic predisposition, immunological response, and environmental pollutants.AR traditionally has been classified as seasonal (SAR) or perennial (PAR) depending on the causes and duration of symptoms. Some patients with AR prefer complementary and alternative medicine for their symptoms, with nearly 20% receiving acupuncture. According to the updated practice parameter of rhinitis in 2020, the use of acupuncture for the treatment of AR was not recommended due to a lack of well-controlled studies.\n\nThe sphenopalatine ganglion (SPG), located under a thin (1-2 mm) layer of mucosa in the pterygopalatine fossa, consists of sensory fibers that innervate the nasopharynx, nasal cavity, and palate.Several studies have reported the benefit of SPG stimulation in chronic cluster headache and acute ischaemic stroke. Compared with traditional acupoints selected on basis of traditional meridian theory, acupuncture at SPG(inserting a needle through SPG acupoint (near ST7, Xiaguan) to reach and directly stimulate the SPG) may help patients ameliorate nasal symptoms immediately and improve quality of life by increasing sympathetic nerve excitability, but the evidence is inconclusive.\n\nWe have designed this three-armed, randomized trial to investigate the efficacy and safety of acupuncture at SPG for the treatment of SAR. We hypothesize that acupuncture at SPG plus rescue medication is superior to sham acupuncture plus RM and RM alone in the treatment of SAR.",[27],"2025-07-13",{"date":217,"type":33},"2025-07-16",{"date":219,"type":33},"2021-05-01",{"date":221,"type":21},"2026-12-31",{"name":223,"class":40},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":231,"targetDuration":4,"studyType":54,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":133},"100581136","phase-2-phase-iiiii-seamless-clinical-study-of-mg-k10-humanized-monoclonal-antibody-injection-in-treatment-of-seasonal-allergic-rhinitis-100581136","NCT06846385","Phase II\u002FIII Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II\u002FIII Seamless Clinical Study Evaluating the Efficacy, Safety, PK, PD, and ADA of MG-K10 Humanized Monoclonal Antibody Injection in the Treatment of Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n* Age of 18-75 years old (including the cutoff value), male or female;\n* With reference to the diagnosis and treatment of allergic rhinitis China guide (2022 revision) \"subjects conforms to the diagnosis of seasonal allergic rhinitis, history 2 years or more clear, at the same time, at least one over the same period of the current season or allergic rhinitis disease related Skin prick test (Skin Prick Test, SPT) or serum Specific IgE (sIgE) (acceptable within less than 1 year before randomization), and the results met the diagnostic criteria for SAR\n* During the previous pollen season, the subjects used nasal corticosteroids or other SAR drugs (antihistamines, leukotriene receptor antagonists, etc.), and their SAR symptoms were poorly controlled.\n* The following criteria were met at screening and baseline:\n\n  1. iTNSS score at screening ≥6, nasal congestion ≥2, runny nose, nasal itching, and sneezing 3. One of the symptoms ≥2 points;\n  2. iTNSS score ≥6 at baseline; rTNSS≥6 points, nasal congestion ≥2 points, runny nose, nose,one of the three symptoms of itching and sneezing ≥2 points\n* Throughout the study period (from signing the ICF to 6 months after the study drug administration), fertile female subjects and their partners agreed to use highly effective birth control, and male subjects and their partners agreed to use effective birth control and had no plans to donate sperm (men) or eggs (women)\n* Be able to understand and comply with clinical protocol requirements, voluntarily participate in clinical trials, and subjects voluntarily sign written informed consent.\n\nExclusion Criteria:\n\n* Allergy to the study drug or its excipients;\n* Travel plans for 48 hours or more from known pollen areas during the screening\u002Finduction and treatment periods (visit 5);\n* The subject's exposure to allergens in his or her home or work environment may have changed significantly during the trial, which the investigator determines may affect the efficacy evaluator;\n* Subjects with limited outdoor activities during the day were defined as those who did not have any outdoor activities during the day for 1 or 4 days per week.\n\n  ·Patients who have previously received anti-interleukin-4 receptor alpha (IL-4Rα) monoclonal antibody drugs (such as dupriuzumab) for Allergic Rhinitis (AR) have poor response (such as treatment failure or treatment intolerance);\n* Use of antihistamines within 4 days prior to randomization;\n* Leukotriene receptor antagonists and hypertrophic cell membrane stabilizers were used within 1 week before randomization;\n* Received medium - and short-acting Systemic Crticosteroids (SCS, including oral, intravenous and intramuscular glucocorticoids) and Chinese medicine for AR treatment (systemic Chinese medicine preparation) within 4 weeks before randomization. Had received long-acting SCS (such as triamcinolone olone injection) within 6 weeks prior to randomization, or planned to receive these medications during the study period;\n* Participants with asthma who began inhaled glucocorticoid therapy within the first 4 weeks of randomization.\n* Stable dose inhaled glucocorticoids were used for at least 4 weeks and evaluated before randomization\n* The dose of inhaled glucocorticoids was maintained during the study period, while the dosage of inhaled glucocorticoids was ≤1000 μg\u002F day of fluticasone propionate or equivalent doses of other inhaled glucocorticoids\n* Randomized 8 weeks or 5 Systemic immunosuppressants (including but not limited to methotrexate, cyclosporine, mycophenolate, tacrolimus, penicillamine, sulfasulazopyridine, hydroxychloroquine, azathioprine, cyclophosphamide) have been used within a half-life (whichever is longer) to treat inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic disease) Lupus erythematosus, multiple sclerosis, etc);\n* random or 10 weeks before 5 within the half-life of longer (in time) received anti IL - 4 r alpha monoclonal antibody, Thymic Stromal lymphocytes (Thymic Stromal Lymphopoietin, TSLP) monoclonal antibody, anti-IGE monoclonal antibody, other monoclonal antibody or other biologic agent therapy;\n* Participated in MG-K10 clinical trials;\n* Live\u002Fattenuated vaccine received within 3 months prior to randomization or during the planned study period; Subjects who started Immunotherapy \\[including Intravenous Immunoglobin (IVIG) therapy or Specific Immunotherapy (SIT) therapy\\] within 6 months before randomization, Participants who plan to begin immunotherapy during the study;\n* Had received any nasal or sinus surgery within 1 year prior to randomization;\n* History of vital organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002Fbone marrow transplantation\n* Other nasal comorbiditis or co-occurring diseases\u002Fconditions (such as acute\u002Fchronic sinusitis, nasal polyps, deviation of nasal septum, drug-induced rhinitis, cerebrospinal fluid rhinorrhea, nasal postoperative status within 1 year, etc.) were present at the time of screening and could affect the efficacy evaluation as assessed by the investigators;\n* Acute sinusitis, nasal infection, or upper respiratory tract infection during the screening\u002Finduction period or within 2 weeks prior to screening;\n* Have malignant or benign tumors in the nasal cavity;\n* Screening for infections requiring treatment with systemic antimicrobials, antivirals, antifungals, antiparasites or antigenics within 7 days prior to the visit;\n* Patients with Perennial Allergic Rhinitis (PAR) who are allergic to pet hair (if the subject is currently free of pet hair contact) may be included. PAR subjects who are allergic to other indoor allergens may be included);\n* Have a history of lymphoproliferative diseases, or have had or are present with malignant tumors within 5 years prior to screening (except for skin squamous cell carcinoma in situ, basal cell carcinoma, and cervical carcinoma in situ after thorough treatment without any signs of recurrence);\n* Have a history or evidence of high risk cardiovascular disease\n* Have posterior subcapsular cataracts or glaucoma, or any other eye condition that may affect the evaluation of eye symptoms, or related conditions listed below\n* Active TB infection is present or suspected;\n* Presence or suspected worm infection within 6 months;\n* A history of severe herpes virus infection, such as herpes encephalitis, disseminated herpes, etc.\n* Patients with severe diseases of the central nervous system, respiratory system, liver, kidney, gastrointestinal, urinary, endocrine, or blood systems that the investigator believes may affect the efficacy and safety of the subject;\n* Known or suspected immunosuppressed individuals, including, but not limited to, a history of invasive opportunistic infections (e.g., tuberculosis, histoplasmosis, listeriosis, coccidioidosis, pulmonary cyst disease, aspergillosis), even if the infection has resolved; Or unusual frequent, recurrent, or long-term infections (as determined by the investigator)\n* The presence of any significant laboratory anomalies\n* Pregnant or lactating women, or those with a positive pre-randomized serum pregnancy test\n* According to the judgment of the researcher, it is not suitable to participate in this researcher for other reasons.",{"count":232,"type":21},160,[96,188],"A multicenter, randomized, double-blind, placebo-controlled Phase II\u002FIII seamless clinical study evaluating the efficacy, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, and immunogenicity of MG-K10 humanized monoclonal antibody injection in the treatment of seasonal allergic rhinitis",[27],[237],"Seasonal allergic rhinitis","2025-04-15",{"date":240,"type":33},"2025-04-18",{"date":242,"type":33},"2025-03-20",{"date":244,"type":21},"2025-09-30",{"name":246,"class":108},"Shanghai Mabgeek Biotech.Co.Ltd"]